Matthew Luchini
Stock Analyst at BMO Capital
(2.08)
# 2,960
Out of 5,072 analysts
34
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $9.53 | +214.80% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $1.75 | +10,757.14% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $21.00 | +228.57% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $22.99 | +352.37% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $2.48 | +2,117.74% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $12.12 | +733.33% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $787.32 | -19.98% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $592.04 | -79.06% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $127.12 | -49.65% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $35.46 | -60.52% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.11 | +5,305.41% | 2 | Dec 3, 2019 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $9.53
Upside: +214.80%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $1.75
Upside: +10,757.14%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $21.00
Upside: +228.57%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $22.99
Upside: +352.37%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $2.48
Upside: +2,117.74%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $12.12
Upside: +733.33%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $787.32
Upside: -19.98%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $592.04
Upside: -79.06%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $127.12
Upside: -49.65%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $35.46
Upside: -60.52%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.11
Upside: +5,305.41%